Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3853-3858

  Bartsch, Rupert ^a   Wenzel, Catharina ^a   Altorjai, Gabriela ^a   Pluschnig, Ursula ^a   Rudas, Margaretha ^a   Mader, Robert M ^a   Gnant, Michael ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; NAVELBINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY; TAXOID; VINBLASTINE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BRAIN TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DIARRHEA; DISEASE COURSE; DRUG ADMINISTRATION; FEMALE; HEMATOLOGIC DISEASE; MIDDLE AGED; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT FAILURE; VINBLASTINE;

EID: 34548543191     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9776     Document Type: Article

References (28)

1. Faneyte IF, Peterse JL, Van Tinteren H, et al: Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 10:4457-4463, 2004
2. Beslija S, Bonneterre J, Burstein H, et al: Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18:215-225, 2007
3. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-182, 1987
4. Boss JS, Fletcher JA, Linette GP: The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307-325, 2003
5. Paik S, Hazan R, Fisher ER, et al: Pathologic finding from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein expression in primary breast cancer. J Clin Oncol 8:103-112, 1990
6. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 4:650-655, 1991
7. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443, 2006
8. Nahta R, Yu D, Hung MC, et al: Mechanisms of Disease: Understanding resistance to Her2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology 3:269-280, 2006
9. Harris M, Smith I: The development and clinical use of trastuzumab (Herceptin). Endocrine-Related Cancer 9:75-85, 2002
10. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
11. Fountzilas G, Razis E, Tsavdaridis D, et al: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic cooperative oncology group. Clin Breast Cancer 4:120-125, 2003
12. Tripathy D, Slamon D, Cobleigh M, et al: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 6:1063-1070, 2004
13. Bartsch R, Wenzel C, Hussian D, et al: Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 6:63, 2006
14. Blum JL: The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56-64, 2001
15. Pegram M, Hsu S, Lewis G, Pietras R, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
16. Leyland-Jones B, Gelmon K, Ayoub JP, et al: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971, 2003
17. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and Vinorelbine as first-line therapy forHer2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895, 2003
18. Pierga JY, Fumoleau P, Brewer Y, et al: Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 88:117-129, 2004
19. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y: Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 49:211-216, 2002
20. Bangemann N, Kuhle A, Ebert A, et al: Capecitabine combined with trastuzumab in the therapy of intensively pre-treated HER2-overexpressing metastatic breast cancer (MBC). Ann Oncol 11:S143, 2000 (suppl 4)
21. Xu L, Song S, Zhu J, et al: A phase II trial of trastuzumab (H) + capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer. J Clin Oncol 24:577s, 2006 (suppl; abstr 10615)
22. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
23. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768, 2001
24. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
25. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977, 2003
26. Shmueli E, Wigler N, Inbar M: Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40:379-382, 2004
27. Clayton AJ, Danson S, Jolly S, et al: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643, 2004
28. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006